BioSyent to Present at the 2014 Marcum MicroCap Investor Conference

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO Rene
Goehrum will be making a presentation at the Marcum MicroCap Conference at 11am
(ET), May 29, 2014 at the Grand Hyatt Hotel in New York City. Mr. Goehrum will
provide an overview of the Company and its corporate activities.


The presentation will be webcast live and may be accessed by visiting the
Investor Center at the www.biosyent.com website or at the following conference
link http://wsw.com/webcast/marcum2/bioyf. A replay of the webcast will be
available for 90 days after the presentation date. The annual Marcum MicroCap
Conference is a signature showcase for superior quality, under-followed public
companies with less than $500 million in market capitalization.


Mr. Goehrum will be available for 1:1 meetings after his presentation.These
meetings can be arranged via the conference organizers
http://www.marcumllp.com/microcap.


To view and listen to the CEO presentation commenting on First Quarter 2014
Financial Results released May 16, 2014, please visit the following link
http://www.biosyent.com/q1/. 


For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada.


At the date of this press release the Company had 13,776,195 shares issued and
outstanding.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
[phone]
[e-mail]
www.biosyent.com